Short-term tolerability and dose toxicity evaluation of 177Lu-DOTATATE for advanced neuroendocrine tumors (NET)

#3459

Introduction: 177Lu-DOTATATE has become a valuable treatment option in the management of advanced NET. However, PRRT treatment is usually limited by kidney toxicity, where the radiopharmaceutical is reabsorbed and retained, or bone marrow by evident hematological toxicity or in the liver.

Aim(s): Evaluate kidney, liver and hematological toxicity during 177LuDOTATATE treatment in clinical practice.

Materials and methods: We included 116 stand-alone 177Lu-DOTATATE doses administered. A retrospective descriptive study of 30 patients with differentiated advanced NET Ki-67<20% treated with 177Lu-DOTATATE between 2013–2021. An average activity of 7.3GBq 177Lu-DOTATATE per dose was administered at intervals of 8-10 weeks in four cycles. Patient baseline demographic characteristics, as well as clinical, analytical and tumor-related data were recorded from the medical history.

Conference:

Presenting Author: Bonilla Plaza J

Authors: Bonilla Plaza J, Martinez Lorca A, Navarro Martinez T, Azpeitia Hernandez P, Alonso-Gordoa T,

Keywords: PRRT, 177Lu, Toxicity,